 In this study, we assessed the safety of combined propofol and midazolamsidation in cirrhotic patients undergoing upper gastrointestinal endoscopy, UGE. We found that there was no significant difference between the safety and rate of complications for the cirrhotic and non-cirrhotic patients except for the recovery period during the first 10 minutes. The modified Aldredi score for the cirrhotic patients was 9.5 plus or minus 0.5 minutes as compared to 9.8 plus or minus 0.4 minutes, p less than 0.001, at 10 minutes. Grade II hepatic encephalopathy was seen in 0.8 percent of the cirrhotic patients who required hospitalization for 24 hours. Balanced sedation was also acceptable by both the patients and the endoscopists with statistically significant scores on assessment of co-operation and patient satisfaction scores. Overall, our results suggest that combined propofol and midazolamsidation can be safely used in cirrhotic patients undergoing UGE. This article was authored by Lyma Alam, Muhammad Asif Kotak and Mufaza Alam.